BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang T, Zhou C. The past, present and future of immunotherapy against tumor. Transl Lung Cancer Res 2015;4:253-64. [PMID: 26207213 DOI: 10.3978/j.issn.2218-6751.2015.01.06] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
Number Citing Articles
1 Jiang T, Qiao M, Zhao C, Li X, Gao G, Su C, Ren S, Zhou C. Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis. Cancer Immunol Immunother 2018;67:713-27. [PMID: 29423649 DOI: 10.1007/s00262-018-2126-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
2 Oyer JL, Gitto SB, Altomare DA, Copik AJ. PD-L1 blockade enhances anti-tumor efficacy of NK cells. Oncoimmunology 2018;7:e1509819. [PMID: 30377572 DOI: 10.1080/2162402X.2018.1509819] [Cited by in Crossref: 56] [Cited by in F6Publishing: 37] [Article Influence: 14.0] [Reference Citation Analysis]
3 Sun D, Ma J, Wang J, Han C, Qian Y, Chen G, Li X, Zhang J, Cui P, Du W, Wu Z, Chen S, Zheng X, Yue Z, Song J, Gao C, Zhao X, Cai S, Hu Y. Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. Cancer Immunol Immunother 2019;68:1527-35. [PMID: 31535160 DOI: 10.1007/s00262-019-02386-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
4 Huo M, Zhao Y, Satterlee AB, Wang Y, Xu Y, Huang L. Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. J Control Release 2017;245:81-94. [PMID: 27863995 DOI: 10.1016/j.jconrel.2016.11.013] [Cited by in Crossref: 75] [Cited by in F6Publishing: 83] [Article Influence: 12.5] [Reference Citation Analysis]
5 Saavedra D, Crombet T. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. Front Immunol 2017;8:269. [PMID: 28348561 DOI: 10.3389/fimmu.2017.00269] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
6 Stavraka C, Blagden S. The La-Related Proteins, a Family with Connections to Cancer. Biomolecules 2015;5:2701-22. [PMID: 26501340 DOI: 10.3390/biom5042701] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 7.6] [Reference Citation Analysis]
7 Barliana MI, Diantini A, Subarnas A, Abdulah R, Izumi T. Inhibition of Phosphorylated c-Jun NH(2)-terminal Kinase by 2',4'-dihydroxy-6-methoxy-3,5-dimethylchalcone Isolated from Eugenia aquea Burm f. Leaves in Jurkat T-cells. Pharmacogn Mag 2017;13:S573-7. [PMID: 29142417 DOI: 10.4103/pm.pm_16_17] [Reference Citation Analysis]
8 Zaurito AE, Tschurtschenthaler M. Microenvironmental Metabolites in the Intestine: Messengers between Health and Disease. Metabolites 2022;12:46. [PMID: 35050167 DOI: 10.3390/metabo12010046] [Reference Citation Analysis]
9 Šmahel M. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. Int J Mol Sci 2017;18:E1331. [PMID: 28635644 DOI: 10.3390/ijms18061331] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
10 Petersen CT, Krenciute G. Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma. Front Oncol 2019;9:69. [PMID: 30863720 DOI: 10.3389/fonc.2019.00069] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 11.0] [Reference Citation Analysis]
11 Cheng L, Liu J, Liu Q, Liu Y, Fan L, Wang F, Yu H, Li Y, Bu L, Li X, Wei W, Wang H, Sun G. Exosomes from Melatonin Treated Hepatocellularcarcinoma Cells Alter the Immunosupression Status through STAT3 Pathway in Macrophages. Int J Biol Sci 2017;13:723-34. [PMID: 28655998 DOI: 10.7150/ijbs.19642] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 8.6] [Reference Citation Analysis]
12 Gao Y, Zheng A, Zhu X, Song J, Xue Q. Clinical benefit from afatinib in an advanced squamous cell lung carcinoma patient harboring HER2 S310Y mutation: a case report. Onco Targets Ther 2018;11:8705-10. [PMID: 30584328 DOI: 10.2147/OTT.S182812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Jiang T, Chen X, Zhou W, Fan G, Zhao P, Ren S, Zhou C, Zhang J. Immunotherapy with Dendritic Cells Modified with Tumor-Associated Antigen Gene Demonstrates Enhanced Antitumor Effect Against Lung Cancer. Transl Oncol 2017;10:132-41. [PMID: 28129580 DOI: 10.1016/j.tranon.2016.12.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
14 Mu W, Chu Q, Liu Y, Zhang N. A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy. Nanomicro Lett 2020;12:142. [PMID: 34138136 DOI: 10.1007/s40820-020-00482-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 12] [Article Influence: 15.5] [Reference Citation Analysis]
15 Chan CW, Tsui SK, Law BM, So WK, Tang FW, Wong CL. The Utilization of the Immune System in Lung Cancer Treatment: Beyond Chemotherapy. Int J Mol Sci 2016;17:286. [PMID: 26927069 DOI: 10.3390/ijms17030286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
16 Li Y, Zhang Z, Hu Y, Yan X, Song Q, Wang G, Chen R, Jiao S, Wang J. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs). Front Oncol 2020;10:654. [PMID: 32656072 DOI: 10.3389/fonc.2020.00654] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
17 Li X, Lan X, Wang G, Liu Y, Zhao K, Lu SZ, Xu XX, Shi GG, Ye K, Zhang BR, Zhao YM, Han HQ, Du CG, Ichim TE, Wang H. Skin Allografting Activates Anti-tumor Immunity and Suppresses Growth of Colon Cancer in Mice. Transl Oncol 2018;11:890-9. [PMID: 29793087 DOI: 10.1016/j.tranon.2018.04.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Kalish SV, Lyamina SV, Usanova EA, Manukhina EB, Larionov NP, Malyshev IY. Macrophages Reprogrammed In Vitro Towards the M1 Phenotype and Activated with LPS Extend Lifespan of Mice with Ehrlich Ascites Carcinoma. Med Sci Monit Basic Res 2015;21:226-34. [PMID: 26471744 DOI: 10.12659/msmbr.895563] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
19 Douam F, Ding Q, Ploss A. Recent advances in understanding hepatitis C. F1000Res. 2016;5:pii: F1000. [PMID: 26918166 DOI: 10.12688/f1000research.7354.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
20 Ballesteros PÁ, Chamorro J, Román-Gil MS, Pozas J, Gómez Dos Santos V, Granados ÁR, Grande E, Alonso-Gordoa T, Molina-Cerrillo J. Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2021;13:5981. [PMID: 34885091 DOI: 10.3390/cancers13235981] [Reference Citation Analysis]
21 Kelm NE, Zhu Z, Ding VA, Xiao H, Wakefield MR, Bai Q, Fang Y. The role of IL-29 in immunity and cancer. Crit Rev Oncol Hematol 2016;106:91-8. [PMID: 27637354 DOI: 10.1016/j.critrevonc.2016.08.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]